Shire headache for FTSE

clock

Having charged across the 5,000 mark yesterday, the FTSE 100 index has shed a couple of points this morning to 4,987.7, paced by Shire Pharmaceuticals Group.

Drugmaker Shire has fallen 60.5p or as much as 9.5% to 581.50p, after Canadian regulators ordered the company to withdraw its biggest selling drug, Adderall XR, as a result of its link to at least 20 deaths. Barclays bank has also dropped 14p to 580p in morning trading even though the lender posted a 14% increase in second-half profit as investment-banking income rose and loan loss provisions declined. Imperial Chemical Industries meanwhile has gained 20.50p or 8% to 266.50p. In Japan the Nikkei 225 Stock Average raced to a seven-month high, advancing 0.7% to 11,553.56 at its close ...

To continue reading this article...

Join Professional Adviser for free

  • Unlimited access to real-time news, industry insights and market intelligence
  • Stay ahead of the curve with spotlights on emerging trends and technologies
  • Receive breaking news stories straight to your inbox in the daily newsletters
  • Make smart business decisions with the latest developments in regulation, investing retirement and protection
  • Members-only access to the editor’s weekly Friday commentary
  • Be the first to hear about our events and awards programmes

Join

 

Already a Professional Adviser member?

Login

More on Investment

Darius McDermott: Defence in a fragmented world

Darius McDermott: Defence in a fragmented world

'It is clear that the world has changed and government spending is being redeployed'

Darius McDermott
clock 01 May 2026 • 4 min read
Canaccord Wealth launches crypto exposure offering to high-net-worth clients

Canaccord Wealth launches crypto exposure offering to high-net-worth clients

For risk profile 7+ portfolios

clock 29 April 2026 • 1 min read
RBC Brewin Dolphin adds to Voyager range with passive funds

RBC Brewin Dolphin adds to Voyager range with passive funds

With six risk options

Patrick Brusnahan
clock 27 April 2026 • 1 min read